KEYNOTE-641: A Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer

Julie N. Graff, Li Wen Liang, Jeri Kim, Arnulf Stenzl

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Current treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) are noncurative, and median survival upon development of mCRPC is approximately 3 years. The novel hormonal agent enzalutamide has an established role in the mCRPC treatment paradigm, and emerging evidence suggests potential synergism with enzalutamide and the PD-1 inhibitor pembrolizumab in men with mCRPC. Here, we describe the design and rationale for the multicenter, randomized, double-blind, Phase III KEYNOTE-641 study, which will be conducted to compare the efficacy and safety of pembrolizumab plus enzalutamide with that of enzalutamide plus placebo in mCRPC. Clinical trial registration: NCT03834493 (ClinicalTrials.gov.

Original languageEnglish (US)
Pages (from-to)3017-3026
Number of pages10
JournalFuture Oncology
Volume17
Issue number23
DOIs
StatePublished - Aug 2021

Keywords

  • PD-1
  • PD-L1
  • castration resistant
  • enzalutamide
  • mCRPC
  • pembrolizumab
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'KEYNOTE-641: A Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this